Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Gilead Sciences (NASDAQ:GILD) and increased the price target from $82 to $85.
January 23, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has maintained an Equal-Weight rating on Gilead Sciences and raised the price target from $82 to $85, indicating a positive outlook on the stock.
The increase in price target by Barclays reflects a positive sentiment towards Gilead Sciences' stock, suggesting that the analyst sees potential for the stock to rise to the new target price. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100